Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 arimoclomol versus placebo in amyotrophic lateral sclerosis
NL-OMON48938Phase 3Active, not recruiting
- Sponsor
- Orphazyme A/S
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Arimoclomol with Placebo (2 arms). Primary endpoint: Combined Assessment of Function and Survival. Started Feb 2019; status: active, not recruiting.
02
Drugs
arimoclomol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON48938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48938.